Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter June 1, 2005

Frequency of –163 C > A and 63 C > G single nucleotide polymorphism of cytochrome P450 1A2 in two African populations

  • Collet Dandara , Patience T. Basvi , Tashinga E. Bapiro , Jane Sayi and Julia A. Hasler

Abstract

Cytochrome P450 1A2 (CYP1A2) is an important member of the cytochrome P450 superfamily of enzymes because of its involvement in the metabolism of some carcinogens and therapeutically important drugs. As a result, factors affecting the activity of the enzyme are the focus of considerable research effort as they may have important pharmacological or toxicological implications. CYP1A2 has been shown to exhibit a genetic polymorphism with most of the data, however, coming from studies in Caucasian and Oriental populations. In this study therefore, we investigated the frequencies of two point mutations, –163C > A and 63C > G, in two Bantu African populations. A total of 214 healthy subjects were recruited from Zimbabwe (n = 143) and Tanzania (n = 71). The two single nucleotide polymorphisms were detected using polymerase chain reaction-restriction fragment length polymorphism analysis. The frequency of –163A was 57% (95% confidence interval (CI), 54%, 60%) and 49% (95% CI, 45%, 53%) among Zimbabweans and Tanzanians, respectively, but the difference between the two populations was not statistically significant (p = 0.123). The base change 63C > G was not found in any of the subjects from the two populations. We report here a high frequency of –163C > A base change and an absence of the 63C > G change in the two African populations.


Corresponding author (present address): Collet Dandara, Division of Medical Biochemistry, Faculty of Health Sciences, University of Cape Town, South Africa. Phone: 27 21 406 6266, Fax: 27 21 406 6061, E-mail:

References

1 Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens, and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270:414–23.Search in Google Scholar

2 Eiermann B, Engel G, Johansson I, Zanger UM, Bertilsson L. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Pharmacol 1997; 44:439–46.10.1046/j.1365-2125.1997.t01-1-00605.xSearch in Google Scholar

3 Yoshimura R, Ueda N, Nakamura J, Eto S, Matsushita M. Interaction between fluvoxamine and cotinine or caffeine. Neuropsychobiology 2002; 45:32–5.10.1159/000048670Search in Google Scholar

4 Breinholt VM, Offord EA, Brouwer C, Nielsen SE, Brosen K, Friedberg T. In vitro investigation of cytochrome P450-mediated metabolism of dietary flavonoids. Food Chem Toxicol 2002; 40:609–16.10.1016/S0278-6915(01)00125-9Search in Google Scholar

5 Sofowora GG, Choo EF, Mayo G, Shyr Y, Wilkinson GR. In vivo inhibition of human CYP1A2 activity by oltipraz. Cancer Chemother Pharmacol 2001; 47:505–10.10.1007/s002800000245Search in Google Scholar PubMed

6 Cusack BJ, Dawson GW, Mercer GD, Vestal RE. Cigarette smoking and theophylline metabolism: effects of cimetidine. Clin Pharmacol Ther 1985; 37:330–6.10.1038/clpt.1985.48Search in Google Scholar PubMed

7 Huang J-D, Guo W-C, Lai M-D, Guo Y-L, Lambert GH. Detection of a novel cytochrome P450 1A2 polymorphism (F21L) in Chinese. Drug Metab Dispos 1999; 27:98–101.Search in Google Scholar

8 Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, Hayes RB, et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992; 2:116–27.10.1097/00008571-199206000-00003Search in Google Scholar PubMed

9 Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 2002; 34:83–448.10.1081/DMR-120001392Search in Google Scholar PubMed

10 Murayama N, Soyama A, Saito Y, Nakajima Y, Komamura K, Ueno K, et al. Six novel nonsynonymous CYP1A2 gene polymorphisms: catalytic activities of the naturally occurring variant enzymes. J Pharmacol Exp Ther 2004; 308:300–6.10.1124/jpet.103.055798Search in Google Scholar PubMed

11 Sachse C, Brockmoller J, Bauer S, Roots I. Functional significance of a C-A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. J Clin Pharmacol 1999; 47:445–9.10.1046/j.1365-2125.1999.00898.xSearch in Google Scholar PubMed PubMed Central

12 Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T. Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on CYP1A2 inducibility in humans. J Biochem 1999; 125:803–8.10.1093/oxfordjournals.jbchem.a022352Search in Google Scholar PubMed

13 Aklillu E, Carrillo JA, Makonnen E, Hellman K, Pitarque M, Bertilsson L, et al. Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterisation of novel haloptypes with single-nucleotide polymorphisms in intron 1. Mol Pharmacol 2003; 64:659–69.10.1124/mol.64.3.659Search in Google Scholar

14 Basile VS, Ozdemir V, Masellis M, Walker ML, Meltzer HY, Lieberman JA, et al. A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Mol Psychiatry 2000; 5:410–7.10.1038/sj.mp.4000736Search in Google Scholar

15 Hamdy SI, Hiratsuka M, Narahara K, El-Enany M, Moursi N, Ahmed MS, et al. Genotyping of four genetic polymorphisms in the CYP1A2 gene in the Egyptian population. Br J Clin Pharmacol 2003; 55:321–4.10.1046/j.1365-2125.2003.01787.xSearch in Google Scholar

16 Nordmark A, Lundgren S, Ask B, Granath F, Rane A. The effect of the CYP1A2*1F mutation on CYP1A2 inducibility in pregnant women. Br J Clin Pharmacol 2002; 54:504–10.10.1046/j.1365-2125.2002.01673.xSearch in Google Scholar

17 Han XM, Ouyang DS, Chen XP, Shu Y, Jiang CH, Tan ZR, et al. Inducibility of CYP1A2 by omeprazole in vivo related to genetic polymorphism of CYP1A2. Br J Clin Pharmacol 2002; 54:540–3.10.1046/j.1365-2125.2002.01686.xSearch in Google Scholar

18 Masimirembwa CM, Beke M, Hasler JA, Tang B-K, Kalow W. Low CYP1A2 activity in rural Shona children of Zimbabwe. Clin Pharmacol Ther 1995; 7:25–31.10.1016/0009-9236(95)90262-7Search in Google Scholar

19 Wooding SP, Watkins WS, Bamshad MJ, Dunn DM, Weiss RB, Jorde LB. DNA sequence variation in a 3.7-kb noncoding sequence 5′ of the CYP1A2 gene\implications for human population history and natural selection. Am J Hum Genet 2002; 71:528–42.10.1086/342260Search in Google Scholar PubMed PubMed Central

Received: 2004-1-30
Accepted: 2004-5-3
Published Online: 2005-6-1
Published in Print: 2004-8-1

© Walter de Gruyter

Downloaded on 29.3.2024 from https://www.degruyter.com/document/doi/10.1515/CCLM.2004.152/html
Scroll to top button